Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

NCOR2 controls androgen deprivation therapy failure in advanced prostate cancer through re-wiring of the onco-epigenome [RNA-seq]

ABSTRACT: NCOR2 is frequently and significantly mutated in late stage androgen deprivation therapy resistant prostate cancer (ADT-RPCa). NCOR2 has been characterized as a transcriptional corepressor and has mechanistic links to DNA methylation, but its global functions and overall contributions to PCa progression remain enigmatic. We mapped the dihydrotestosterone (DHT) dependent and independent effects of NCOR2 on the transcriptome, cistrome and DNA methylome in androgen sensitive (AS) and ADT-RPCa cells using the isogenic LNCaP and LNCaP-C4-2 (C4-2) cell models and the CWR22 xenograft model of ADT-RPCa.

ORGANISM(S): Homo sapiens

PROVIDER: GSE180373 | GEO | 2021/11/17

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

NCOR2 controls androgen deprivation therapy failure in advanced prostate cancer through re-wiring of the onco-epigenome [CWR22_EPIC]

Project description:NCOR2 is frequently and significantly mutated in late stage androgen deprivation therapy resistant prostate cancer (ADT-RPCa). NCOR2 has been characterized as a transcriptional corepressor and has mechanistic links to DNA methylation, but its global functions and overall contributions to PCa progression remain enigmatic. We mapped the dihydrotestosterone (DHT) dependent and independent effects of NCOR2 on the transcriptome, cistrome and DNA methylome in androgen sensitive (AS) and ADT-RPCa cells using the isogenic LNCaP and LNCaP-C4-2 (C4-2) cell models and the CWR22 xenograft model of ADT-RPCa.

2021-11-17 | GSE178819 | GEO

NCOR2 controls androgen deprivation therapy failure in advanced prostate cancer through re-wiring of the onco-epigenome [CellLine_EPIC]

2021-11-17 | GSE178818 | GEO

NCOR2 controls androgen deprivation therapy failure in advanced prostate cancer through re-wiring of the onco-epigenome [ChIP-seq]

2021-11-17 | GSE180372 | GEO

NCOR2 controls androgen deprivation therapy failure in advanced prostate cancer through re-wiring of the onco-epigenome [CWR22 xenograft]

2021-11-17 | GSE179133 | GEO

NCOR2 controls androgen deprivation therapy failure in advanced prostate cancer through re-wiring of the onco-epigenome [CWR22 xenograft]

Project description:NCOR2 controls androgen deprivation therapy failure in advanced prostate cancer through re-wiring of the onco-epigenome [CWR22 xenograft]

| PRJNA742392 | ENA

Identification of Radiosensitivity Gene Signatures Induced by Enzalutamide in Prostate cancer cells

Project description:This study aimed to identify gene signatures induced by enzalutamide (ENZA) in hormone-sensitive (LNCaP) and hormone-resistant prostate cancer (PCa) cells. LNCaP and C4-2 cells were treated with ENZA alone or in combination with androgen deprivation therapy (ADT) and radiation (XRT). Through gene expression profiling, we identified that ENZA alone or in combination with ADT enhanced the effect the effect of XRT through immune-related pathways in LNCaP cells and metabolic pathways in C4-2 cells.Kaplan-Meier curve and Cox propotional hazard models showed that low expression of all the candidate genes except PTPRN2 were associated with tumor progression and recurrence in a PCa cohort.

2019-07-01 | GSE126881 | GEO

Hypoxia-independent downregulation of hypoxia inducible factor 1 targets by androgen deprivation therapy in prostate cancer.

Project description:Hypoxia inducible factor 1 (HIF1) has been shown to cooperate with the androgen receptor (AR) in activation of oncogenic pathways in prostate cancer (PCa). Here we hypothesized that HIF1 also plays a role in PCa response to androgen deprivation therapy (ADT). Comparison of gene expression profiles of androgen exposed (AE) and androgen deprived (AD) CWR22 PCa xenografts identified 596 upregulated and 748 downregulated genes after ADT. Gene ontology (GO) analysis of the differentially expressed genes showed significant enrichment of the biological processes cell proliferation, cell cycle and metabolism and suggested suppression of these processes after ADT. A set of 80 hypoxia-inducible genes were identified in 22Rv1 and LNCaP cell lines treated with hypoxia and showed considerable overlap (53%) with the downregulated genes. Immunostaining of the hypoxia marker pimonidazole showed no difference between AE- and AD-tumors. Comparison of the differentially expressed genes with lists of 1115 direct AR- and 276 direct HIF1-target genes identified 138 AR- and 40 HIF1-targets that were regulated after ADT, including six shared AR- and HIF1-targets for which downregulation was confirmed with RT-PCR. Most HIF1-targets were downregulated and included in the significant biological processes and the set of hypoxia-inducible genes. The downregulation of HIF1-targets was consistent with decreased HIF1A immunostaining in AD- compared to AE-tumors (p=0.002). A decrease in HIF1A immunostaining after ADT was also demonstrated in a cohort of 35 PCa patients (p<0.001). These data suggest suppressed HIF1-signaling after ADT and a shared role of HIF1 and AR in the regressive phase of PCa after ADT. Prostate cancer xenografts were subjected to adrogen deprivation therapy and analysed with regard to changes in gene expressions. Cell culture experiments were performed to generate prostate cancer specific gene lists associated with hypoxia.

2013-10-02 | E-GEOD-42868 | biostudies-arrayexpress

Hypoxia-independent downregulation of hypoxia inducible factor 1 targets by androgen deprivation therapy in prostate cancer.

2013-10-02 | GSE42868 | GEO

NCOR2 controls androgen deprivation therapy failure in advanced prostate cancer through re-wiring of the onco-epigenome

Project description:NCOR2 controls androgen deprivation therapy failure in advanced prostate cancer through re-wiring of the onco-epigenome

| PRJNA741199 | ENA

NCOR2 controls androgen deprivation therapy failure in advanced prostate cancer through re-wiring of the onco-epigenome [CWR22_EPIC]

Project description:NCOR2 controls androgen deprivation therapy failure in advanced prostate cancer through re-wiring of the onco-epigenome [CWR22_EPIC]

| PRJNA741201 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data